Literature DB >> 20965206

Sodium arsenite delays the differentiation of C2C12 mouse myoblast cells and alters methylation patterns on the transcription factor myogenin.

Amanda A Steffens1, Gia-Ming Hong, Lisa J Bain.   

Abstract

Epidemiological studies have correlated arsenic exposure with cancer, skin diseases, and adverse developmental outcomes such as spontaneous abortions, neonatal mortality, low birth weight, and delays in the use of musculature. The current study used C2C12 mouse myoblast cells to examine whether low concentrations of arsenic could alter their differentiation into myotubes, indicating that arsenic can act as a developmental toxicant. Myoblast cells were exposed to 20 nM sodium arsenite, allowed to differentiate into myotubes, and expression of the muscle-specific transcription factor myogenin, along with the expression of tropomyosin, suppressor of cytokine signaling 3 (Socs3), prostaglandin I2 synthesis (Ptgis), and myocyte enhancer 2 (Mef2), was investigated using QPCR and immunofluorescence. Exposing C2C12 cells to 20 nM sodium arsenite delayed the differentiation process, as evidenced by a significant reduction in the number of multinucleated myotubes, a decrease in myogenin mRNA expression, and a decrease in the total number of nuclei expressing myogenin protein. The expression of mRNA involved in myotube formation, such as Ptgis and Mef2 mRNA, was also significantly reduced by 1.6-fold and 4-fold during differentiation. This was confirmed by immunofluorescence for Mef2, which showed a 2.6-fold reduction in nuclear translocation. Changes in methylation patterns in the promoter region of myogenin (-473 to +90) were examined by methylation-specific PCR and bisulfite genomic sequencing. Hypermethylated CpGs were found at -236 and -126 bp, whereas hypomethylated CpGs were found at -207 bp in arsenic-exposed cells. This study indicates that 20 nM sodium arsenite can alter myoblast differentiation by reducing the expression of the transcription factors myogenin and Mef2c, which is likely due to changes in promoter methylation patterns. The delay in muscle differentiation may lead to developmental abnormalities.
© 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20965206      PMCID: PMC3014457          DOI: 10.1016/j.taap.2010.10.006

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  58 in total

1.  Exposure to sodium metam during zebrafish somitogenesis results in early transcriptional indicators of the ensuing neuronal and muscular dysfunction.

Authors:  Fred Tilton; Robert L Tanguay
Journal:  Toxicol Sci       Date:  2008-07-22       Impact factor: 4.849

2.  DNA hypermethylation of promoter of gene p53 and p16 in arsenic-exposed people with and without malignancy.

Authors:  Sarmishtha Chanda; Uma B Dasgupta; Debendranath Guhamazumder; Mausumi Gupta; Utpal Chaudhuri; Sarbari Lahiri; Subhankar Das; Nilima Ghosh; Debdutta Chatterjee
Journal:  Toxicol Sci       Date:  2005-10-26       Impact factor: 4.849

3.  Transplacental carcinogenicity of inorganic arsenic in the drinking water: induction of hepatic, ovarian, pulmonary, and adrenal tumors in mice.

Authors:  Michael P Waalkes; Jerrold M Ward; Jie Liu; Bhalchandra A Diwan
Journal:  Toxicol Appl Pharmacol       Date:  2003-01-01       Impact factor: 4.219

4.  Association of arsenic exposure during pregnancy with fetal loss and infant death: a cohort study in Bangladesh.

Authors:  Anisur Rahman; Marie Vahter; Eva-Charlotte Ekström; Mahfuzar Rahman; Abu Haider Mohammad Golam Mustafa; Mohammad Abdul Wahed; Mohammed Yunus; Lars-Ake Persson
Journal:  Am J Epidemiol       Date:  2007-03-10       Impact factor: 4.897

5.  Regulation of skeletal muscle sarcomere integrity and postnatal muscle function by Mef2c.

Authors:  Matthew J Potthoff; Michael A Arnold; John McAnally; James A Richardson; Rhonda Bassel-Duby; Eric N Olson
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

6.  mef2c is activated directly by myogenic basic helix-loop-helix proteins during skeletal muscle development in vivo.

Authors:  Evdokia Dodou; Shan-Mei Xu; Brian L Black
Journal:  Mech Dev       Date:  2003-09       Impact factor: 1.882

7.  Animal models for arsenic carcinogenesis: inorganic arsenic is a transplacental carcinogen in mice.

Authors:  Michael P Waalkes; Jie Liu; Jerrold M Ward; Bhalchandra A Diwan
Journal:  Toxicol Appl Pharmacol       Date:  2004-08-01       Impact factor: 4.219

8.  Inhibition of myoblast migration by prostacyclin is associated with enhanced cell fusion.

Authors:  Brenda A Bondesen; Kristen A Jones; Wayne C Glasgow; Grace K Pavlath
Journal:  FASEB J       Date:  2007-05-08       Impact factor: 5.191

9.  Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene.

Authors:  P Hasty; A Bradley; J H Morris; D G Edmondson; J M Venuti; E N Olson; W H Klein
Journal:  Nature       Date:  1993-08-05       Impact factor: 49.962

Review 10.  Arsenic and cardiovascular disease.

Authors:  J Christopher States; Sanjay Srivastava; Yu Chen; Aaron Barchowsky
Journal:  Toxicol Sci       Date:  2008-11-17       Impact factor: 4.849

View more
  22 in total

1.  Arsenic exposure inhibits myogenesis and neurogenesis in P19 stem cells through repression of the β-catenin signaling pathway.

Authors:  Gia-Ming Hong; Lisa J Bain
Journal:  Toxicol Sci       Date:  2012-05-28       Impact factor: 4.849

2.  Methylmercury modifies temporally expressed myogenic regulatory factors to inhibit myoblast differentiation.

Authors:  Megan Culbreth; Matthew D Rand
Journal:  Toxicol In Vitro       Date:  2019-11-06       Impact factor: 3.500

3.  Sodium arsenite represses the expression of myogenin in C2C12 mouse myoblast cells through histone modifications and altered expression of Ezh2, Glp, and Igf-1.

Authors:  Gia-Ming Hong; Lisa J Bain
Journal:  Toxicol Appl Pharmacol       Date:  2012-03-09       Impact factor: 4.219

4.  Assessment of arsenic trioxide toxicity on cock muscular tissue: alterations of oxidative damage parameters, inflammatory cytokines and heat shock proteins.

Authors:  Si-Wen Li; Ying Guo; Ying He; Xiao Sun; Hong-Jing Zhao; Yu Wang; Ya-Jun Wang; Ming-Wei Xing
Journal:  Ecotoxicology       Date:  2017-07-28       Impact factor: 2.823

5.  Arsenic exposure to killifish during embryogenesis alters muscle development.

Authors:  Kristen M Gaworecki; Robert W Chapman; Marion G Neely; Angela R D'Amico; Lisa J Bain
Journal:  Toxicol Sci       Date:  2011-11-04       Impact factor: 4.849

6.  Oxidation state specific analysis of arsenic species in tissues of wild-type and arsenic (+3 oxidation state) methyltransferase-knockout mice.

Authors:  Jenna M Currier; Christelle Douillet; Zuzana Drobná; Miroslav Stýblo
Journal:  J Environ Sci (China)       Date:  2016-07-18       Impact factor: 5.565

7.  The methyl-CpG-binding protein CIBZ suppresses myogenic differentiation by directly inhibiting myogenin expression.

Authors:  Yu Oikawa; Reiko Omori; Tomonori Nishii; Yasumasa Ishida; Masashi Kawaichi; Eishou Matsuda
Journal:  Cell Res       Date:  2011-05-31       Impact factor: 25.617

8.  Arsenic inhibits hedgehog signaling during P19 cell differentiation.

Authors:  Jui Tung Liu; Lisa J Bain
Journal:  Toxicol Appl Pharmacol       Date:  2014-10-30       Impact factor: 4.219

9.  Arsenic induces sustained impairment of skeletal muscle and muscle progenitor cell ultrastructure and bioenergetics.

Authors:  Fabrisia Ambrosio; Elke Brown; Donna Stolz; Ricardo Ferrari; Bret Goodpaster; Bridget Deasy; Giovanna Distefano; Alexandra Roperti; Amin Cheikhi; Yesica Garciafigueroa; Aaron Barchowsky
Journal:  Free Radic Biol Med       Date:  2014-06-21       Impact factor: 7.376

10.  Arsenic Stimulates Myoblast Mitochondrial Epidermal Growth Factor Receptor to Impair Myogenesis.

Authors:  Amin Cheikhi; Teresa Anguiano; Jane Lasak; Baoli Qian; Amrita Sahu; Hikaru Mimiya; Charles C Cohen; Peter Wipf; Fabrisia Ambrosio; Aaron Barchowsky
Journal:  Toxicol Sci       Date:  2020-07-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.